Johnson & Johnson JNJ NYSE

Johnson & Johnson (JNJ) generated $24.53B in operating cash flow for fiscal year 2025. After capital expenditures of $4.83B, free cash flow was $19.7B.

Free cash flow margin was 20.9% of revenue. Cash conversion ratio was 0.92x, suggesting some earnings are non-cash.

The company returned $12.38B in dividends and $5.95B in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (100/100, Pass) — $19.7B (20.9% FCF margin) supports a durable competitive advantage
• INCOME (85/100) — Cash conversion ratio was 0.92x suggests some earnings are non-cash items

Overall SharesGrow Score: 73/100 with 4/7 criteria passed.